About
Dr. Amy Kruse is an American neuroscientist, innovation leader, and venture capitalist renowned as the Chief Investment Officer of Satori Neuro, a stage-agnostic investment fund under Satori Capital dedicated to mental health, neurotechnology, and human flourishing breakthroughs. With over two decades of experience, she pioneered DARPA's first performance-oriented neuroscience programs as a program manager, driving advances in augmented cognition, accelerated learning, and neuromodulation; later served as VP/CTO at Cubic Global Defense and CSO at Optios; and was a General Partner at Prime Movers Lab investing in human augmentation. Holding a BS in Cell and Structural Biology and PhD in Neuroscience from the University of Illinois Urbana-Champaign, Kruse now identifies and supports transformative companies in brain health while serving on multiple portfolio boards.